Publication Details

Category Text Publication
Reference Category Journals
DOI 10.3390/vaccines11091469
Licence creative commons licence
Title (Primary) An efficient and scalable method for the production of immunogenic SARS-CoV-2 virus-like particles (VLP) from a mammalian suspension cell line
Author Hirschberg, S.; Ghazaani, F.; Ben Amor, G.; Pydde, M.; Nagel, A.; Germani, S.; Monica, L.; Schlör, A.; Bauer, H.; Hornung, J.; Voetz, M.; Dwai, Y.; Scheer, B.; Ringel, F.; Kamal-Eddin, O.; Harms, C.; Füner, J.; Adrian, L.; Pruß, A.; Schulze-Forster, K.; Hanack, K.; Kamhieh-Milz, J.
Source Titel Vaccines
Year 2023
Department UBT
Volume 11
Issue 9
Page From art. 1469
Language englisch
Topic T7 Bioeconomy
Keywords virus-like particle (VLP); SARS-CoV-2; vaccine; stable cell line; neutralizing antibodies
Abstract The rapid evolution of new SARS-CoV-2 variants poses a continuing threat to human health. Vaccination has become the primary therapeutic intervention. The goal of the current work was the construction of immunogenic virus-like particles (VLPs). Here, we describe a human cell line for cost-efficient and scalable production of immunogenic SARS-CoV-2 VLPs. The modular design of the VLP-production platform facilitates rapid adaptation to new variants. Methods: The N, M-, and E-protein genes were integrated into the genome of Expi293 cells (ExpiVLP_MEN). Subsequently, this cell line was further modified for the constitutive expression of the SARS-CoV-2 spike protein. The resulting cell line (ExpiVLP_SMEN) released SARS-CoV-2 VLP upon exposure to doxycycline. ExpiVLP_SMEN cells were readily adapted for VLP production in a 5 L bioreactor. Purified VLPs were quantified by Western blot, ELISA, and nanoparticle tracking analysis and visualized by electron microscopy. Immunogenicity was tested in mice. Results: The generated VLPs contained all four structural proteins, are within the size range of authentic SARS-CoV-2 virus particles, and reacted strongly and specifically with immunoserum from naturally infected individuals. The VLPs were stable in suspension at 4 °C for at least 10 weeks. Mice immunized with VLPs developed neutralizing antibodies against lentiviruses pseudotyped with the SARS-CoV-2 spike protein. The flexibility of the VLP-production platform was demonstrated by the rapid switch of the spike protein to a new variant of concern (BA.1/Omicron). The present study describes an efficient, scalable, and adaptable production method of immunogenic SARS-CoV-2 VLPs with therapeutic potential.
Persistent UFZ Identifier
Hirschberg, S., Ghazaani, F., Ben Amor, G., Pydde, M., Nagel, A., Germani, S., Monica, L., Schlör, A., Bauer, H., Hornung, J., Voetz, M., Dwai, Y., Scheer, B., Ringel, F., Kamal-Eddin, O., Harms, C., Füner, J., Adrian, L., Pruß, A., Schulze-Forster, K., Hanack, K., Kamhieh-Milz, J. (2023):
An efficient and scalable method for the production of immunogenic SARS-CoV-2 virus-like particles (VLP) from a mammalian suspension cell line
Vaccines 11 (9), art. 1469 10.3390/vaccines11091469